CAMBRIDGE, Mass. — April 3, 2019 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics™, is pleased to participate in a number of upcoming conferences and symposia.
Dr. Deya Corzo, Chief Medical Officer of Sigilon, is one of a select group of experts invited to attend the 2nd World Federation of Hemophilia Gene Therapy Round Table in Montreal on April 4-5. The round table serves as a forum for participants to discuss the challenges and opportunities of gene therapy for hemophilia around the world.
Additionally, Sigilon will host a booth to engage with patients, scientists and physicians in the hemophilia community at the Hemophilia Federation of America’s annual symposium, April 4-9 in San Diego.
Finally, Dr. Rogerio Vivaldi, Chief Executive Officer of Sigilon, will provide updates on Sigilon’s exciting pipeline progress at the inaugural Cell & Gene Meeting on the Mediterranean hosted by the Alliance for Regenerative Medicine in Barcelona. Dr. Vivaldi will present a corporate overview on April 23 at 4:45pm CET. Additionally, he will participate in a panel entitled “Recent Developments and Predictions for the Future of Advanced Therapies” on April 24 at 9:15am CET.
About Sigilon Therapeutics
Sigilon Therapeutics is a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics. To create Shielded Living Therapeutics, we engineer novel human cells that we encase in a proprietary immune-shielding matrix and place in the body. These Shielded Living Therapeutics then produce therapeutic proteins in a programmable and durable fashion, without generating fibrosis or immune rejection.Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.